LT3481846T - 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles - Google Patents
11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būklesInfo
- Publication number
- LT3481846T LT3481846T LTEP17742595.6T LT17742595T LT3481846T LT 3481846 T LT3481846 T LT 3481846T LT 17742595 T LT17742595 T LT 17742595T LT 3481846 T LT3481846 T LT 3481846T
- Authority
- LT
- Lithuania
- Prior art keywords
- hydroxysterols
- substituted
- treatment
- related conditions
- nmda related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359532P | 2016-07-07 | 2016-07-07 | |
| PCT/US2017/041199 WO2018009867A1 (en) | 2016-07-07 | 2017-07-07 | Oxysterols and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3481846T true LT3481846T (lt) | 2021-08-25 |
Family
ID=59383635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17742595.6T LT3481846T (lt) | 2016-07-07 | 2017-07-07 | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10781231B2 (enExample) |
| EP (2) | EP3481846B1 (enExample) |
| JP (2) | JP6966486B2 (enExample) |
| AU (3) | AU2017292870B2 (enExample) |
| CY (1) | CY1124631T1 (enExample) |
| DK (1) | DK3481846T3 (enExample) |
| ES (1) | ES2884071T3 (enExample) |
| HR (1) | HRP20211272T8 (enExample) |
| HU (1) | HUE055263T2 (enExample) |
| LT (1) | LT3481846T (enExample) |
| MA (1) | MA45598B1 (enExample) |
| MD (1) | MD3481846T2 (enExample) |
| PL (1) | PL3481846T3 (enExample) |
| PT (1) | PT3481846T (enExample) |
| RS (1) | RS62222B1 (enExample) |
| SI (1) | SI3481846T1 (enExample) |
| SM (1) | SMT202100468T1 (enExample) |
| TW (1) | TWI752976B (enExample) |
| WO (1) | WO2018009867A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN111777654B (zh) * | 2020-06-11 | 2021-08-10 | 浙江神洲药业有限公司 | 一种泼尼松的制备方法 |
| EP4351588A1 (en) | 2021-06-11 | 2024-04-17 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115057906B (zh) * | 2022-07-28 | 2022-12-02 | 中节能万润股份有限公司 | 利用去氢表雄酮合成胆固醇的方法 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| ATE254628T1 (de) | 1995-06-23 | 2003-12-15 | Novo Nordisk As | Meiose regulierende verbindungen. |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| JP4313435B2 (ja) * | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| HUE062616T2 (hu) * | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CN112057457A (zh) | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| IL271343B2 (en) | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
| SG11202004329TA (en) | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2017
- 2017-07-07 WO PCT/US2017/041199 patent/WO2018009867A1/en not_active Ceased
- 2017-07-07 ES ES17742595T patent/ES2884071T3/es active Active
- 2017-07-07 SI SI201730870T patent/SI3481846T1/sl unknown
- 2017-07-07 EP EP17742595.6A patent/EP3481846B1/en active Active
- 2017-07-07 MA MA45598A patent/MA45598B1/fr unknown
- 2017-07-07 SM SM20210468T patent/SMT202100468T1/it unknown
- 2017-07-07 HR HRP20211272TT patent/HRP20211272T8/hr unknown
- 2017-07-07 LT LTEP17742595.6T patent/LT3481846T/lt unknown
- 2017-07-07 DK DK17742595.6T patent/DK3481846T3/da active
- 2017-07-07 US US16/315,250 patent/US10781231B2/en active Active
- 2017-07-07 EP EP21172788.8A patent/EP3919502A1/en not_active Withdrawn
- 2017-07-07 TW TW106122956A patent/TWI752976B/zh active
- 2017-07-07 PL PL17742595T patent/PL3481846T3/pl unknown
- 2017-07-07 JP JP2018568810A patent/JP6966486B2/ja active Active
- 2017-07-07 PT PT177425956T patent/PT3481846T/pt unknown
- 2017-07-07 MD MDE20190582T patent/MD3481846T2/ro unknown
- 2017-07-07 RS RS20211006A patent/RS62222B1/sr unknown
- 2017-07-07 AU AU2017292870A patent/AU2017292870B2/en active Active
- 2017-07-07 HU HUE17742595A patent/HUE055263T2/hu unknown
-
2020
- 2020-07-30 US US16/943,649 patent/US11279730B2/en active Active
-
2021
- 2021-08-06 CY CY20211100708T patent/CY1124631T1/el unknown
- 2021-08-16 JP JP2021132225A patent/JP2021175761A/ja not_active Withdrawn
- 2021-09-17 AU AU2021232833A patent/AU2021232833B2/en active Active
-
2023
- 2023-12-28 AU AU2023286014A patent/AU2023286014B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202100468T1 (it) | 24-idrossisteroli sostituiti in posizione 11 per l'uso nel trattamento delle condizioni correlate all'nmda | |
| IL260257A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| IL256175A (en) | Using exosomes to treat the disease | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumors | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| EP3215157B8 (en) | Apilimod for use in the treatment of melanoma | |
| HUE054065T2 (hu) | Szerek glióma kezelésében történõ alkalmazásra | |
| SI3592355T1 (sl) | KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze | |
| PT3160464T (pt) | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento | |
| LT3373922T (lt) | Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| PT3548006T (pt) | Composição para utilização no tratamento de alterações intestinais | |
| HUE066000T2 (hu) | (+)-Azaszetron fül rendellenességek kezelésében történõ alkalmazásra | |
| GB201615844D0 (en) | Agents for use in therapy | |
| GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases | |
| ZA201408464B (en) | Composition for the use in treatment of asthma |